New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
09:29 EDTNWBONorthwest CEO gave 'conflicting language' on timeline, Feuerstein says
The CEO of Northwest Biotherapeutics, Linda Powers, offered "conflicting language" yesterday regarding the timeline for enrollment of 312 glioblastoma patients in the phase III study of the experimental cancer vaccine DC-Vax, The Street's Adam Feuerstein writes. Reference Link
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
09:08 EDTNWBONorthwest Biotherapeutics begins first treatment with DCVax-L in Germany
Subscribe for More Information
October 7, 2014
09:07 EDTNWBONorthwest Biotherapeutics raises $11.5M through an institutional stock sale
Northwest Biotherapeutics announced that the Company has entered into an agreement with a single existing institutional shareholder for the purchase and sale of approximately $11.5M of newly issued shares of the Company's Common Stock at a price of $5.05 per share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.
09:05 EDTNWBONorthwest Biotherapeutics enters into $11.5M financing agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use